ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL924
CHEMBL924
Compound Name ZOLEDRONIC ACID
ChEMBL Synonyms ZOLEDRONATE DISODIUM | RECLAST | ZOMETA | ZOLEDRONIC ACID | ZOLEDRONATE TRISODIUM | CGP 42446 | ACLASTA | CGP 42446B | CGP 42446A | ZERLINDA
Max Phase 4 (Approved)
Trade Names RECLAST | ZOLEDRONIC ACID | ZOMETA | ACLASTA | ZERLINDA
Molecular Formula C5H10N2O7P2

Additional synonyms for CHEMBL924 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES OC(Cn1ccnc1)(P(=O)(O)O)P(=O)(O)O
Standard InChI InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4 ...
Download InChI
Standard InChI Key XRASPMIURGNCCH-UHFFFAOYSA-N

Sources

  • British National Formulary
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL924

Molecule Features

CHEMBL924 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Farnesyl diphosphate synthase inhibitor Farnesyl diphosphate synthase FDA PubMed PubMed PubMed PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Breast NeoplasmsD001943EFO:0000305breast carcinoma3ClinicalTrials
Breast NeoplasmsD001943EFO:0003869breast neoplasm3ClinicalTrials
Osteitis DeformansD010001EFO:0004261osteitis deformans3ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma3ClinicalTrials
Reflex Sympathetic DystrophyD012019EFO:1001147reflex sympathetic dystrophy3ClinicalTrials
Sarcoma, EwingD012512EFO:0000174Ewing sarcoma3ClinicalTrials
Urogenital NeoplasmsD014565EFO:0003863urogenital neoplasm2ClinicalTrials
AdenocarcinomaD000230EFO:0000228adenocarcinoma1ClinicalTrials
Osteoporosis, PostmenopausalD015663EFO:0003854postmenopausal osteoporosis3ClinicalTrials
Prostatic NeoplasmsD011471EFO:0000196metastatic prostate cancer3ClinicalTrials
Uterine Cervical NeoplasmsD002583EFO:0001416cervical adenocarcinoma2ClinicalTrials
Fractures, BoneD050723EFO:0003931bone fracture3ClinicalTrials
ProgeriaD011371Orphanet:740Hutchinson-Gilford progeria syndrome2ClinicalTrials
beta-ThalassemiaD017086Orphanet:848Beta-thalassemia2ClinicalTrials
Anemia, Sickle CellD000755Orphanet:232Sickle cell anemia1ClinicalTrials
Carcinoma, HepatocellularD006528EFO:0000182hepatocellular carcinoma2ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma3ClinicalTrials
Nasopharyngeal NeoplasmsD009303EFO:0004252nasopharyngeal neoplasm2ClinicalTrials
PlasmacytomaD010954EFO:0006738plasmacytoma3ClinicalTrials
Carcinoma, Renal CellD002292EFO:0002890renal carcinoma2ClinicalTrials
ChondrosarcomaD002813EFO:0000333chondrosarcoma1ClinicalTrials
MenopauseD008593EFO:0003922menopause1ClinicalTrials
MesotheliomaD008654EFO:0000588mesothelioma2ClinicalTrials
OsteoporosisD010024EFO:0003882osteoporosis3ClinicalTrials
SarcomaD012509EFO:0000691sarcoma3ClinicalTrials
Lymphoma, Non-HodgkinD008228EFO:0005952non-Hodgkins lymphoma3ClinicalTrials
Primary MyelofibrosisD055728EFO:0002430primary myelofibrosis2ClinicalTrials
Prostatic NeoplasmsD011471EFO:0000673prostate adenocarcinoma3ClinicalTrials
Carcinoma, Intraductal, NoninfiltratingD002285EFO:0000432ductal carcinoma in situ2ClinicalTrials
Carcinoma, Renal CellD002292EFO:0000681renal cell carcinoma2ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveD015464EFO:0000339chronic myelogenous leukemia2ClinicalTrials
Lung NeoplasmsD008175EFO:0001071lung carcinoma3ClinicalTrials
Osteogenesis ImperfectaD010013Orphanet:666Osteogenesis imperfecta3ClinicalTrials
OsteosarcomaD012516EFO:0000637osteosarcoma2ClinicalTrials
PainD010146EFO:0003843pain3ClinicalTrials
Spinal Cord InjuriesD013119EFO:1001919Spinal cord injury3ClinicalTrials
Arthritis, RheumatoidD001172EFO:0000685rheumatoid arthritis3ClinicalTrials
Bone DiseasesD001847EFO:0004260bone disease4ATC
Bone Diseases, MetabolicD001851HP:0000938osteopenia3ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma3ClinicalTrials
NeuroblastomaD009447EFO:0000621neuroblastoma1ClinicalTrials
OsteonecrosisD010020EFO:0004259osteonecrosis2ClinicalTrials
Uterine Cervical NeoplasmsD002583EFO:0001061cervical carcinoma2ClinicalTrials

Clinical Data

ClinicalTrials.gov ZOLEDRONIC ACID
The Cochrane Collaboration ZOLEDRONIC ACID

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL924. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL1782 Farnesyl diphosphate synthase Homo sapiens 1.000
CHEMBL3693 Farnesyl pyrophosphate synthase Leishmania donovani 1.000
CHEMBL5141 Cytochrome P450 26A1 Homo sapiens 1.000
CHEMBL4028 Thromboxane-A synthase Rattus norvegicus 1.000
CHEMBL4430 Cytochrome P450 17A1 Rattus norvegicus 1.000
CHEMBL1835 Thromboxane-A synthase Homo sapiens 0.990
CHEMBL1908 Cytochrome P450 11B1 Homo sapiens 0.983
CHEMBL4521 Cytochrome P450 24A1 Homo sapiens 0.981
CHEMBL3859 Cytochrome P450 19A1 Rattus norvegicus 0.972
CHEMBL4508 Glutaminyl-peptide cyclotransferase Homo sapiens 0.906
CHEMBL340 Cytochrome P450 3A4 Homo sapiens 0.900
CHEMBL1978 Cytochrome P450 19A1 Homo sapiens 0.895
CHEMBL3522 Cytochrome P450 17A1 Homo sapiens 0.886
CHEMBL4769 Geranylgeranyl pyrophosphate synthetase Homo sapiens 0.694
CHEMBL5831 Farnesyl diphosphate synthase Toxoplasma gondii 0.593
CHEMBL4607 Angiotensin II type 2 (AT-2) receptor Homo sapiens 0.578
CHEMBL4527 TRAF2- and NCK-interacting kinase Homo sapiens 0.289
CHEMBL2722 Cytochrome P450 11B2 Homo sapiens 0.233



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL1782 Farnesyl diphosphate synthase Homo sapiens 1.000
CHEMBL3693 Farnesyl pyrophosphate synthase Leishmania donovani 1.000
CHEMBL4028 Thromboxane-A synthase Rattus norvegicus 1.000
CHEMBL5141 Cytochrome P450 26A1 Homo sapiens 1.000
CHEMBL4769 Geranylgeranyl pyrophosphate synthetase Homo sapiens 1.000
CHEMBL5035 Heme oxygenase 1 Rattus norvegicus 1.000
CHEMBL4430 Cytochrome P450 17A1 Rattus norvegicus 1.000
CHEMBL1835 Thromboxane-A synthase Homo sapiens 0.999
CHEMBL4521 Cytochrome P450 24A1 Homo sapiens 0.991
CHEMBL1978 Cytochrome P450 19A1 Homo sapiens 0.980
CHEMBL3348 Heme oxygenase 2 Rattus norvegicus 0.979
CHEMBL1908 Cytochrome P450 11B1 Homo sapiens 0.961
CHEMBL3859 Cytochrome P450 19A1 Rattus norvegicus 0.951
CHEMBL3522 Cytochrome P450 17A1 Homo sapiens 0.884
CHEMBL4607 Angiotensin II type 2 (AT-2) receptor Homo sapiens 0.714
CHEMBL5831 Farnesyl diphosphate synthase Toxoplasma gondii 0.707
CHEMBL2722 Cytochrome P450 11B2 Homo sapiens 0.602
CHEMBL4508 Glutaminyl-peptide cyclotransferase Homo sapiens 0.483
CHEMBL4527 TRAF2- and NCK-interacting kinase Homo sapiens 0.292
CHEMBL3553 Tyrosine-protein kinase TYK2 Homo sapiens 0.249

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
272.1 271.9963 -1.12 4 153.11 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
5 5 0 9 5 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
1.41 6.78 .62 -4.39 1 16 0.43

Structural Alerts

There are 5 structural alerts for CHEMBL924. To view alerts please click here.

Compound Cross References

ATC M - MUSCULO-SKELETAL SYSTEM
M05 - DRUGS FOR TREATMENT OF BONE DISEASES
M05B - DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05BA - Bisphosphonates
M05BA08 - zoledronic acid

ChemSpider ChemSpider:XRASPMIURGNCCH-UHFFFAOYSA-N
DailyMed zoledronic acid
PubChem SID: 144205292 SID: 174006914 SID: 29215499
Wikipedia Zoledronic_acid

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL924



ACToR 118072-93-8
BindingDB 12578
Brenda 6184 189166
ChEBI 46557
ChemicalBook CB4395643
DrugBank DB00399
DrugCentral 2868
eMolecules 902698
EPA CompTox Dashboard DTXSID0042668
FDA SRS 70HZ18PH24
Guide to Pharmacology 3177
Human Metabolome Database HMDB0014543
IBM Patent System CA001CD9DB8E227A332C4E1CFFAA2409
Mcule MCULE-1604726355
Nikkaji J556.181G
PDBe ZOL
PharmGKB PA10235
PubChem 68740
PubChem: Thomson Pharma 14824151
Selleck Zoledronic-Acid
SureChEMBL SCHEMBL19054
ZINC ZINC000003803652

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/XRASPMIURGNCCH-UHFFFAOYSA-N spacer
spacer